A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

X

Trial Profile

A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ebselen (Primary)
Indications Noise-induced hearing loss
Focus Therapeutic Use
Acronyms PANIHL
Sponsors Sound Pharmaceuticals

Most Recent Events

22 Aug 2018 Planned End Date changed from 1 Sep 2019 to 1 Oct 2021.
22 Aug 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Jun 2021.
22 Aug 2018 Planned initiation date changed from 1 Feb 2018 to 1 Nov 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com